CTOs on the Move

Kyverna Therapeutics

www.kyvernatx.com

 
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases. Our therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of disease. Kyverna is venture-backed and located in the San Francisco East Bay.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Karen Walker
Chief Technology Officer Profile

Funding

Kyverna Therapeutics raised $25M on 01/13/2020

Similar Companies

Sarepta Therapeutics

Sarepta Therapeutics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tunnell Consulting

Tunnell Consulting is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Hydra Biosciences

Hydra Biosciences is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STAT PHARMACEUTICALS

STAT PHARMACEUTICALS is a Santee, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spero Therapeutics

Spero is a multi-asset, clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts dedicated to identifying, developing and commercializing novel treatments focused on unmet needs of patients with multidrug-resistant (MDR) bacterial infections. Spero`s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. Spero also has a platform technology known as its Potentiator Platform that it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. Spero`s lead product candidates generated from its Potentiator Platform are two intravenous, or IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting. Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial infection.